Introduction
============

NANOG is a transcription factor that contains a DNA-binding domain, and acts to maintain pluripotency, self-renewal, and the undifferentiated state of embryonic stem cells.[@b1-ott-11-5515] It belongs to the *NK-2* gene of the ANTP superfamily, which is primarily expressed in the blastocyst inner cell mass.[@b2-ott-11-5515] However, cancer stem cells (CSCs) involved in tumor recurrence and metastasis express NANOG as a surface marker in addition to CD133, CD90, EpCAM, and CD44.[@b3-ott-11-5515],[@b4-ott-11-5515] NANOG protein expression is a biomarker that indicates poor clinical outcome in lung, breast, gastric, colorectal, pancreatic, and ovarian cancer as well as in hepatocellular, oral squamous cell, esophageal, and nasopharyngeal carcinoma.[@b5-ott-11-5515]--[@b14-ott-11-5515] Ravindran et al reported that elevated NANOG expression was associated with poor overall survival (OS) and disease-free survival (DFS), lymph node metastasis, tumor stage, and differentiation of oral squamous cell carcinoma (OSCC),[@b15-ott-11-5515] but Hwang et al found no association of NANOG expression with clinical stage or OS.[@b10-ott-11-5515] Vaz et al found that NANOG expression was not related to prognosis in rectal cancer.[@b16-ott-11-5515] Therefore, the prognostic value of NANOG expression in solid tumors is controversial. This meta-analysis was conducted to overcome design limitations and sample size limitations of previous studies to further evaluate the potential prognostic and clinical values of NANOG in patients with malignant cancers.

Materials and methods
=====================

Search strategy
---------------

Articles published through May 31, 2018 were retrieved from PubMed, the Web of Science, Embase, and the China National Knowledge Infrastructure (CNKI). Combinations of the MeSH headings and keywords "NANOG or NANOG homeobox protein or NANOGP8", "cancer or malignancy or neoplasm or tumor or carcinoma", and "prognosis or outcome or survival" were used in the searches. The reference lists of the retrieved articles were searched manually to supplement the literature retrieval.

Selection criteria
------------------

Studies with a pathologically confirmed solid tumor diagnosis, immunohistochemical (IHC) assay of NANOG expression in primary and tumor tissue, OS and/or DFS as primary outcomes, and reporting HRs with 95% CIs for OS and DFS or with the possibility of calculating them from survival curves were eligible. Moreover, the inclusion criteria included stratification of patients into NANOG-positive and - negative or high and low expression groups for the survival analysis. A sample size of ≥40 cancer patients was required, and the publications were limited to those in English and Chinese. Articles reporting overlapping or duplicate results, lacking information on survival outcomes, reviews, letters, expert opinions, conference abstracts, case reports, and animal studies were excluded. A flow diagram of article selection is shown in [Figure 1](#f1-ott-11-5515){ref-type="fig"}.

Data extraction and quality assessment
--------------------------------------

Two investigators (LZ and JL) independently undertook data extraction and data quality evaluation. Disagreements were resolved by consultation with a third investigator (SC). The study information included the first author, country, language, publication year, cancer type, sample size, follow-up duration, assay methods, cutoff scores, and outcome measures. Patient characteristics included age, sex ratio, tumor differentiation, T stage, tumor size, TNM stage, lymph node metastasis, lymphatic infiltration, and vascular infiltration. HRs and 95% CIs of survival outcome were directly retrieved from the study or were estimated from Kaplan--Meier survival curves. The Newcastle--Ottawa Scale (NOS) was used to evaluate quality of selected literature.[@b17-ott-11-5515] An NOS score ≥5 indicated high quality; low-quality studies were excluded. Discrepancies were resolved through discussion.

Statistical analysis
--------------------

STATA version 14.0 (Stata Corporation, College Station, TX, USA) was used for the meta-analysis, and Engauge Digitizer version 4.1 (<http://markummitchell.github.io/engauge-digitizer/>) was used to extract survival data from Kaplan--Meier curves as previously described by Tierney et al.[@b18-ott-11-5515] HRs and 95% CIs were pooled to estimate the impact of NANOG on OS and DFS. An HR \>1.0 indicated a poor prognosis. ORs and 95% CIs were used to assess the relationship of NANOG expression and clinical pathological features. The chi-squared test and Cochrane's *I*^2^ coefficient were calculated to assess heterogeneity in pooled studies. A chi-square *P*\>0.10 or an *I*^2^\<50% indicated low heterogeneity. If *P* was ≥0.1 and *I*^2^\<50%, the fixed-effects model was used for analysis; otherwise (*P*\<0.1 and/or *I*^2≥^50%), a random-effects model was used, and subgroup analysis was carried out to determine the origin of the heterogeneity. Sensitivity analysis was conducted by continuous omission of individual studies to evaluate the effectiveness and reliability of the meta-analysis. Publication bias was assessed in Begg's funnel plots and Egger's test. *P*\<0.05 was considered as statistically significant.

Results
=======

Study inclusion and characteristics
-----------------------------------

The study selection process is described in [Figure 1](#f1-ott-11-5515){ref-type="fig"}. A total of 33 studies[@b5-ott-11-5515]--[@b16-ott-11-5515],[@b19-ott-11-5515]--[@b39-ott-11-5515] published from 2008--2018 and including 35 data sets with 3,959 patients were selected to evaluate the relationship of NANOG expression and tumor prognosis. The average study population size was 113, ranging from 42 to 312 patients. Twenty studies were conducted in China, five were conducted in Korea, and three in Japan. Twenty-eight were published in English and five in Chinese. Four studies evaluated non-small cell lung cancer (NSCLC),[@b5-ott-11-5515],[@b32-ott-11-5515]--[@b34-ott-11-5515] four evaluated gastric cancer (GC),[@b9-ott-11-5515],[@b26-ott-11-5515],[@b27-ott-11-5515],[@b38-ott-11-5515] and five evaluated OSCC;[@b8-ott-11-5515],[@b15-ott-11-5515],[@b28-ott-11-5515],[@b29-ott-11-5515],[@b36-ott-11-5515] breast cancer,[@b6-ott-11-5515],[@b30-ott-11-5515],[@b31-ott-11-5515] hepatocellular carcinoma (HCC),[@b7-ott-11-5515],[@b25-ott-11-5515],[@b39-ott-11-5515] and ovarian cancer (OC)[@b13-ott-11-5515],[@b21-ott-11-5515],[@b22-ott-11-5515] were each evaluated in three studies. Esophageal squamous cell carcinoma (ESCC),[@b10-ott-11-5515],[@b23-ott-11-5515] colorectal cancer (CRC),[@b11-ott-11-5515],[@b16-ott-11-5515] and pancreatic cancer (PC)[@b12-ott-11-5515],[@b24-ott-11-5515] were each evaluated in two studies. Nasopharyngeal carcinoma (NPC),[@b14-ott-11-5515] astrocytoma,[@b20-ott-11-5515] cervical cancer (CC),[@b37-ott-11-5515] tongue squamous cell carcinoma (TSCC),[@b35-ott-11-5515] and mucoepidermoid carcinoma (MEC)[@b19-ott-11-5515] were each evaluated in one study. Thirty-three studies[@b5-ott-11-5515]--[@b16-ott-11-5515],[@b19-ott-11-5515]--[@b39-ott-11-5515] reported OS and nine studies[@b6-ott-11-5515],[@b9-ott-11-5515],[@b13-ott-11-5515],[@b15-ott-11-5515],[@b21-ott-11-5515],[@b22-ott-11-5515],[@b31-ott-11-5515],[@b32-ott-11-5515],[@b38-ott-11-5515] reported DFS. NANOG expression was assayed in all tumor tissues by IHC and stratified by high and low expression. In most studies, the threshold of high NANOG expression included both staining percentage and intensity scores. Some studies reported the percentage of positively stained cells as the cutoff value. The quality scores of the selected studies ranged from 6 to 8, indicating that they were adequate for inclusion in the quantitative meta-analysis. [Table 1](#t1-ott-11-5515){ref-type="table"} shows the characteristics of the included studies.

High NANOG expression and OS
----------------------------

All 33 articles reported the relationship of the NANOG expression and prognosis. Because of heterogeneity (*I*^2^ = 37%, *P* = 0.016), a random-effects model was used to pool HRs and 95% CIs. High NANOG expression was significantly associated with worse OS (HR = 2.19; 95% CI: 1.87--2.58, *P*\<0.001, [Figure 2](#f2-ott-11-5515){ref-type="fig"}). The effects of NANOG expression on OS in different solid tumors are shown in [Figure 3](#f3-ott-11-5515){ref-type="fig"}. Elevated NANOG expression was significantly related to worse OS in NSCLC (HR = 1.87; 95% CI: 1.26--2.76, *P* = 0.002), head and neck cancers (HR = 2.29; 95% CI: 1.75--3.02, *P*\<0.001), and digestive system cancers (HR = 2.38; 95% CI: 1.95--2.91, *P*\<0.001), which included liver, gastric, colorectal, esophageal, and pancreatic cancer. [Table 2](#t2-ott-11-5515){ref-type="table"} shows the results of subgroup analysis of OS. The pooled HR for OS was 2.26 (95% CI: 1.95--2.62, *P*\<0.001) in Asians and 1.87 (95% CI: 1.08--3.23, *P* = 0.025) in Caucasians. The pooled HR estimate of OS was 2.09 (95% CI: 1.06--2.74, *P*\<0.001) in studies with sample sizes \>100 cases and 2.25 (95% CI: 1.86--2.72, *P*\<0.001) for sample sizes of \<100. The association of high NANOG expression and poor OS was significant in both multivariate (HR = 2.16; 95% CI: 1.77--2.62, *P*\<0.001) and non-multivariate (HR = 2.19; 95% CI: 1.73--2.77, *P*\<0.001) analysis.

High NANOG expression and DFS
-----------------------------

Nine studies[@b6-ott-11-5515],[@b9-ott-11-5515],[@b13-ott-11-5515],[@b15-ott-11-5515],[@b21-ott-11-5515],[@b22-ott-11-5515],[@b31-ott-11-5515],[@b32-ott-11-5515],[@b38-ott-11-5515] with ten data sets reported the association of high NANOG expression and DFS. Because of heterogeneity (*I*^2^ = 64.4%; *P* = 0.003), a random-effects model was used to pool HRs and 95% CI. As shown in [Figure 4](#f4-ott-11-5515){ref-type="fig"}, NANOG expression was associated with worse DFS (HR = 2.21, 95% CI: 1.54--3.18, *P*\<0.001). A subgroup analysis was conducted to investigate the origin of heterogeneity depending on the type of cancer ([Figure 5](#f5-ott-11-5515){ref-type="fig"}). Elevated NANOG expression was significantly associated with worse DFS in ovarian (HR = 2.95; 95% CI: 1.65--5.27, *P*\<0.001), and breast cancer (HR = 4.75; 95% CI: 2.70--8.34, *P*\<0.001) but not NSCLC (HR = 1.23; 95% CI: 0.65--2.36, *P* = 0.524). Additional studies with larger sample sizes are required to reach a consensus.

High NANOG expression: clinical, and pathological characteristics
-----------------------------------------------------------------

High NANOG expression was associated with poor tumor differentiation (OR = 2.63; 95% CI: 1.52--4.55, *P* = 0.001), lymph node metastasis (OR = 2.59; 95% CI: 1.50--4.47, *P* = 0.001), more advanced TNM stage (OR = 2.22; 95% CI: 1.42--3.45, *P*\<0.001), and more advanced T stage (OR = 0.44; 95% CI: 0.20--0.93, *P* = 0.031). NANOG expression was not significantly correlated with age, sex, tumor size, lymphatic infiltration, and vascular infiltration. Because of the lack of data, the relationships of NANOG expression and other clinicopathological variables were not determined. The results are shown in [Table 3](#t3-ott-11-5515){ref-type="table"}.

Sensitivity analysis and publication bias
-----------------------------------------

The sensitivity analysis conducted by sequential deletion of each study to assess the credibility of the pooled results found that no individual study influenced the relationship of NANOG expression and survival outcome ([Figures 6](#f6-ott-11-5515){ref-type="fig"} and [7](#f7-ott-11-5515){ref-type="fig"}). This confirmed the credibility of this meta-analysis. Publication bias was assessed by Begg's funnel plots and Egger's test. The Begg's funnel plots in [Figures 8](#f8-ott-11-5515){ref-type="fig"} and [9](#f9-ott-11-5515){ref-type="fig"} show that there was no significant publication bias in the estimates of OS and DFS. The Egger's test *P*-values of 0.286 for OS and 0.103 for DFS confirmed the lack of significant publication bias.

Discussion
==========

Cancer is a public health problem and the second leading cause of death worldwide, with 1,735,350 new cancer cases and 609,640 cancer deaths projected in the United States in 2018.[@b40-ott-11-5515] Improved understanding of cancer mechanisms and prognosis will help to improve patient survival. *Nanog* gene expression decreases with cell differentiation, and is not detectable in terminally differentiated cells.[@b41-ott-11-5515] However, NANOG protein is overexpressed in germ cell tumors and in many solid tumor types, where it is expressed in CSCs.[@b42-ott-11-5515] The *Nanog* gene is active during the malignant conversion of normal cells; maintains self-renewal of tumor stem cells; regulates the proliferation, migration, and invasion of tumor cells; and promotes tumor immune escape.[@b1-ott-11-5515],[@b43-ott-11-5515],[@b44-ott-11-5515]

Recent preclinical studies have investigated the effects of targeting NANOG expression in CSCs on treatment resistance, invasiveness, and tumorigenesis. Huang et al found that targeting NANOG significantly inhibited the tumorigenicity of CSCs in head and neck squamous cell carcinoma, and increased cisplatin sensitivity.[@b45-ott-11-5515] Tsai et al found that the OCT4 and NANOG expression increased with the development of cisplatin resistance in OSCC tumors.[@b46-ott-11-5515] Stable transfection of NANOG into EC-9706 esophageal cancer cells increases drug resistance by upregulating expression of the multidrug resistance gene *MDR-1*.[@b47-ott-11-5515] Interfering with NANOG-mediated transcription by genome editing, small-molecule inhibitors, transcription factor bait, and small interfering RNA may prove effective for targeting CSCs.[@b48-ott-11-5515] Rad et al demonstrated that ODN decoys downregulated NANOG expression in P19 embryonal cancer cells.[@b49-ott-11-5515] Ding et al reported that the invasiveness and chemoresistance of HeLa cells decreased when NANOG was destroyed by genomic editing with transcriptional activator like effect nuclease (TalEN),[@b50-ott-11-5515] and CRISPR/CAS9 knockout of NANOG or NANOP8 confirmed their involvement in the in vivo tumorigenicity of DU145 prostate cancer cells in an experimental mouse model.[@b51-ott-11-5515] Furthermore, inhibition of NANOG was found to enhance the cytotoxicity of BH3 mimetic targeting of Bcl-2 family members in CRC cells.[@b52-ott-11-5515]

The evidence supports NANOG as a novel indicator of cancer prognosis. Studies of the relationship of clinicopathological variables, NANOG expression, and prognosis are listed in [Table 1](#t1-ott-11-5515){ref-type="table"}. The data of individual studies are inconclusive. This meta-analysis was conducted to clarify the prognostic influence of NANOG expression in solid tumors.

To our knowledge, this meta-analysis is the most thorough appraisal of the clinical studies that investigated the prognostic value of NANOG expression in human solid tumors. Thirty-three eligible studies comprising 35 data sets met the selection criteria. The evidence supports NANOG overexpression as an independent, predictive biomarker of poor OS and DFS in solid tumors. Elevated NANOG expression was associated with poor prognosis in most digestive system cancers (*I*^2^ = 0%), NSCLC (*I*^2^ = 63.9%), and head and neck cancer (*I*^2^ = 0%). Moreover, subgroup analysis indicated that high NANOG expression was significantly correlated with OS regardless of sample size, nationality, or type of analysis, which further supported its prognostic value. Elevated NANOG expression was significantly associated with worse DFS in ovarian and breast cancers but not in NSCLC. Because of the limited number of articles, it cannot be concluded that NANOG expression, when compared with the tumor type, had a greater impact on survival. The sensitivity analysis failed to find the cause of heterogeneity; therefore, the random-effects model was adopted for the combined results. Study heterogeneity may have resulted from differences in follow-up intervals, threshold values of high NANOG expression, and the types of solid tumors studied.

In this meta-analysis, NANOG expression was associated with age in eight, sex in 17, tumor size in four, lymphatic infiltration in four, and vascular infiltration in six studies. The pooled results did not find statistically significant correlations of NANOG expression and those variables. NANOG expression was correlated with TNM stage in 16, tumor differentiation in 18, lymph node metastasis in 16, and T stage in seven studies. The pooled results found that NANOG expression was correlated with tumor differentiation, lymph node metastasis, T stage, and TNM stage.

This meta-analysis was intended to be comprehensive, but it has limitations. First, the threshold value of high NANOG expression was not the same in each study, and may have led to an increase in the heterogeneity. A common cutoff value should be defined. Second, HRs estimated from Kaplan--Meier curves as previously described by Tierney et al might not be as dependable as those extracted directly from the original text of the report, and may have affected the summary analysis. Third, many included studies did not report clinicopathological features, which may lead to bias. Finally, differences in analysis methods, sample sources, follow-up duration, and tumor types might have introduced statistical bias. Additional studies with larger samples and standard testing methods are required to reach a consensus.

Conclusion
==========

Increased NANOG protein expression in various human solid tumors was significantly correlated with poor OS and DFS. NANOG is a potential biomarker to guide clinical treatment and may have prognostic value in human solid tumors. The results of this meta-analysis warrant performance of additional clinical studies of NANOG in human solid tumors.
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###### 

Main characteristics of 33 studies in the meta-analysis

  Study                                  Year   Country    Language   No. of patients   Type of tumor   Follow-up (months)   Cutoff method and scores   Outcome measures   NOS scores
  -------------------------------------- ------ ---------- ---------- ----------------- --------------- -------------------- -------------------------- ------------------ ------------
  Park et al[@b32-ott-11-5515]           2016   Korea      English    142               NSCLC           NA                   SP ≥100                    OS (S)/DFS (S)     7
  Luo et al[@b33-ott-11-5515]            2013   China      Chinese    62                NSCLC           36--60               NA                         OS (S)             7
  Xue et al[@b7-ott-11-5515]             2016   China      Chinese    89                HCC             36                   NA                         OS (S)             7
  Park et al[@b32-ott-11-5515]           2016   Korea      English    226               NSCLC           NA                   SP ≥100                    OS (M)/DFS (M)     7
  Li et al[@b34-ott-11-5515]             2013   China      English    309               NSCLC           52 (7--69.5)         PP ≥5%                     OS (M)             7
  Chang et al[@b5-ott-11-5515]           2017   Korea      English    112               NSCLC           NA                   SP ≥180                    OS (M)             7
  Nagata et al[@b6-ott-11-5515]          2017   Japan      English    208               TNBC            80.7 (20--162)       SP ≥3                      OS (S)/DFS (S)     7
  Jin et al[@b30-ott-11-5515]            2016   China      English    312               BC              60                   PP ≥1%                     OS (M)             7
  Nagata et al[@b31-ott-11-5515]         2014   Japan      English    100               BC              80.7 (20--162)       SP ≥3                      OS (S)/DFS (S)     7
  Li et al[@b9-ott-11-5515]              2015   China      English    69                GC              35 (6--50)           SP ≥5                      OS (S)/DFS (S)     8
  Li et al[@b23-ott-11-5515]             2014   China      Chinese    69                ESCC            65                   PP ≥10%                    OS (S)             8
  Lu et al[@b24-ott-11-5515]             2013   China      English    43                PC              NA                   SP ≥5                      OS (S)             6
  Yin et al[@b25-ott-11-5515]            2012   China      English    228               HCC             60 (1--83)           SP ≥1                      OS (S)             7
  Lin et al[@b26-ott-11-5515]            2012   China      English    105               GC              NA                   SP ≥2                      OS (S)             7
  Matsuoka et al[@b27-ott-11-5515]       2012   Japan      English    253               GC              NA                   SP ≥5                      OS (S)             6
  Hwang et al[@b10-ott-11-5515]          2014   China      English    41                ESCC            13 (0.3--57.4)       NA                         OS (S)             6
  Lee et al[@b28-ott-11-5515]            2015   Korea      English    57                OSCC            35.9 (3--127)        SP ≥4                      OS (M)             7
  Ravindran et al[@b15-ott-11-5515]      2015   India      English    60                OSCC            31.9 (14--48)        PP ≥16%                    OS (M)/DFS (M)     7
  Luo et al[@b14-ott-11-5515]            2013   China      English    122               NPC             60.1 (8--92)         SP ≥6                      OS (S)             7
  Chiou et al[@b29-ott-11-5515]          2008   China      English    52                OSCC            NA                   NA                         OS (S)             6
  Wang et al[@b8-ott-11-5515]            2018   China      English    144               OSCC            62.97 (24--120)      PP ≥50%                    OS (M)             6
  Meng et al[@b11-ott-11-5515]           2010   China      English    175               CRC             NA                   SP ≥4                      OS (S)             6
  Gao et al[@b12-ott-11-5515]            2016   China      English    47                PC              NA                   SP ≥2                      OS (S)             6
  Kenda Šuster et al[@b13-ott-11-5515]   2017   Slovenia   English    106               OC              75 (65.8--84.1)      SP ≥3                      OS (S)/DFS (S)     6
  Elsir et al[@b20-ott-11-5515]          2014   Sweden     English    42                Astrocytoma     NA                   PP ≥50%                    OS (M)             8
  Elsir et al[@b20-ott-11-5515]          2014   Sweden     English    71                Astrocytoma     NA                   PP ≥50%                    OS (M)             8
  Vaz et al[@b16-ott-11-5515]            2014   America    English    100               CRC             69.6                 PP ≥26%                    OS (S)             6
  Xu et al[@b19-ott-11-5515]             2017   China      English    75                MEC             11--124              PP ≥10%                    OS (S)             6
  Lee et al[@b22-ott-11-5515]            2012   Korea      English    74                OC              92 (7--183)          SP ≥4                      OS (M)/DFS (S)     7
  Siu et al[@b21-ott-11-5515]            2013   China      English    90                OC              63 (4--209)          SP At mean                 OS (S)/DFS (S)     7
  Wang et al[@b37-ott-11-5515]           2018   China      Chinese    78                CC              72 (12--144)         SP \>3                     OS (M)             7
  Ouyang et al[@b39-ott-11-5515]         2016   China      Chinese    116               HCC             16.5 (3--36)         SP ≥2                      OS (M)             8
  Zhang et al[@b38-ott-11-5515]          2018   China      Chinese    60                GC              NA                   SP \>2                     OS (S)/DFS (S)     6
  Kim et al[@b36-ott-11-5515]            2017   Korea      English    62                OSCC            35.5                 SP ≥4                      OS (M)             7
  Rodrigues et al[@b35-ott-11-5515]      2018   Brazil     English    60                TSCC            NA                   SP ≥4                      OS (S)             6

**Abbreviations:** BC, breast cancer; NSCLC, non-small cell lung cancer; TNBC, triple-negative breast cancer; ESCC, esophageal squamous cell carcinoma; OSCC, oral squamous cell carcinoma; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; GC, gastric cancer; OC, ovarian cancer; PC, pancreatic cancer; MEC, mucoepidermoid carcinoma; CRC, colorectal cancer; CC, cervical cancer; TSCC, tongue squamous cell carcinoma; PP, percentage of positive cells; SP, staining intensity score and percentage of positive cells; OS, overall survival; DFS, disease-free survival; M, multivariate; S, survival curves; NA, not available.

###### 

Pooled HRs for overall survival according to subgroup analyses

  Categories          Studies (N)   No. of patients   Random-effects model   Heterogeneity          
  ------------------- ------------- ----------------- ---------------------- --------------- ------ ---------
  Overall survival    35            3,959             2.19 (1.87--2.58)      \<0.001         37     \<0.001
  Nationality                                                                                       
   Caucasians         26            2,092             1.87 (1.08--3.23)      0.025           68.7   0.012
   Asians             8             1,805             2.26 (1.95--2.62)      \<0.001         16.8   0.212
  Analysis type                                                                                     
   Multivariate       13            1,663             2.16 (1.77--2.62)      \<0.001         16.6   0.276
   Non-multivariate   22            2,296             2.19 (1.73--2.77)      \<0.001         47     0.008
  Sample size                                                                                       
   ≥100               16            2,758             2.09 (1.06--2.74)      \<0.001         63.8   \<0.001
   \<100              19            1,201             2.25 (1.86--2.72)      \<0.001         0      0.866

###### 

Meta-analytical results of the associations of high NANOG protein expression level with multiple clinicopathological parameters

  Categories                                      Studies (N)   OR (95% CI)         *P*-value   Heterogeneity             
  ----------------------------------------------- ------------- ------------------- ----------- --------------- --------- ----------------
  Age, in years (\>50 vs \<50)                    8             1.0 (0.79--1.26)    1.00        5               0.39      Fixed effects
  Sex (male vs female)                            17            1.01 (0.82--1.25)   0.934       0               0.776     Fixed effects
  Tumor differentiation (moderate/poor vs good)   18            2.63 (1.52--4.55)   0.001       79.9            \<0.001   Random effects
  T stage (T1--2 vs T3--4)                        7             0.44 (0.20--0.93)   0.031       75.3            \<0.001   Random effects
  TNM stage (III/IV vs I/II)                      16            2.22 (1.42--3.45)   ,0.001      55.8            0.004     Random effects
  Tumor size (\>5 cm vs \<5 cm)                   4             1.28 (0.53--3.11)   0.13        78.6            0.003     Random effects
  Lymph node metastasis (yes vs no)               16            2.59 (1.50--4.47)   0.001       77.6            \<0.001   Random effects
  Lymphatic infiltration (yes vs no)              4             1.22 (0.44--3.33)   0.703       79.1            0.002     Random effects
  Vascular infiltration (yes vs no)               6             0.60 (0.38--1.09)   0.103       48.4            0.084     Fixed effects

[^1]: These authors contributed equally to this work
